Atrix License Deal With Fujisawa: Potential $25M.(million, Atrix Laboratories Inc., Fujisawa Healthcare Inc.)(Brief Article)(Statistical Data Included)

Atrix Laboratories Inc. has licensed North American rights for its topical acne treatment, Atrisone, to Fujisawa Healthcare Inc., of Deerfield, III. The deal calls for Fujisawa to pay Atrix, of Fort Collins, Cob., up to $25 million in licensing fees, research and development support and milestone payments. Atrix will manufacture Atrisone and will receive a manufacturing margin …